Adynxx glimpses gain from no-pain drugs

Adynxx's Julien Mamet and Rick Orr.

A team that built and sold three Bay Area drug companies over the past decade is looking for a fourth. But the latest venture, called Adynxx Inc., could be a big pain. The young San Francisco company is entering its first human trial of a treatment to prevent post-surgical pain and, ultimately, chronic pain.

Pain drug developer Adynxx enrolls first trial

Adynxx founder Julien Mamet.

Adynxx Inc., led by a team that has built and sold three other Bay Area drug developers over the past decade, said Tuesday that it has completed enrollment in an early-stage drug trial that could take the pain out of surgery. The 30-person, Phase I study is the first in-human test of AYX-1, the San Francisco company’s experimental preventative treatment for post-surgical pain. The study of healthy volunteers is designed to test the drug’s safety. Adynxx leaders expect to move the drug into a 90- to 100-patient Phase II efficacy trial in the fourth quarter.